Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026.
- Bloom Burton & Co. Healthcare Investor Conference, Toronto, Ontario
Company Presentation: Wednesday, April 22, 2026, 11:30 am–12:00 pm ET - Bank of America Global Healthcare Conference, Las Vegas, NV
Company Presentation: Thursday, May 14, 2026, 8:00–8:30 am PT (11:00–11:30 am ET) - RBC Capital Markets Global Healthcare Conference, New York, NY
Company Presentation: Tuesday, May 19, 2026, 9:30–9:55 am ET - Jeffries Global Healthcare Conference, New York, NY
Company Presentation: Thursday, June 4, 2026, 9:55–10:25 am ET
Details about all company presentations, including webcast information, can be found on the section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit and follow us on and .
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Tucker Kelly
Chief Financial Officer
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
